Klomp, JA, Klomp, JE, Stalnecker, CA, Bryant, KL, Edwards, AC, Drizyte-Miller, K, Hibshman, PS, Diehl, JN, Lee, YS, Morales, AJ, Taylor, KE, Peng, S, Tran, NL, Herring, LE, Prevatte, AW, Barker, NK, Hover, LD, Hallin, J, Chowdhury, S, Coker, O, Lee, HM, Goodwin, CM, Gautam, P, Olson, P, Christensen, JG, Shen, JY, Kopetz, S , Graves, LM, Lim, KH, Wang-Gillam, A, Wennerberg, K, Cox, AD, Der, CJ
Circ Res 84:467474
Immunohistochemistry and western blot analysis reveal ChaC2 downregulation in most tumor tissue, with ChaC2 expression positively correlating with 3-year survival rate (79)
after solution, if applicable, refrigeration required Benefits & unique features 4-in-1 combination of peptides with complementary actions Enhances regenerative pathways through both tissue and skin levels Part of current research models on repair, inflammation and aging High purity and quality makes it suitable for precise studies For research purposes only, not for human use.
The Ghost Trial In the late 1990s and early 2000s, the Croatian pharmaceutical company Pliva sponsored clinical trials for BPC-157 as a treatment for inflammatory bowel disease
